pp-253 Solution for injection
Dossier type
CTD
Dossier status
Under development
Country of origin
China
GMP approvals
China
Comments
Indication: Neovascular age-related macular degeneration / Clinical stage: Phase 3 / Modality: Recombinant humanized monoclonal antibody / Mechanism & Target: Anti-VEGF (vascular endothelial growth factor) inhibition / Route & form: Intravitreal injection / Differentiation: Novel anti-VEGF humanized mAb for retinal neovascularization
Manufacturer #38957
Founded in 2017, this clinical-stage biopharmaceutical company develops Rx antibody biologics for oncology, immunology, ophthalmology, and metabolic diseases. Injectable biologic pipeline is progressing through clinical stages with domestic approvals and an international development strategy. Engages in global licensing partnerships for co-development and commercialization.
Manufacturer usually replies in 31 days
None